Last update 08 May 2025

Flotetuzumab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Anti-CD123/CD3-monoclonal-antibody-MGD006, CD123 x CD3(MacroGenics/Servier), CD123xCD3-DART-bispecific-antibody-MGD006
+ [8]
Action
inhibitors, stimulants
Mechanism
CD123 inhibitors(Interleukin-3 receptor subunit alpha inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11306Flotetuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2--
Myelodysplastic SyndromesPhase 2--
High Risk Myelodysplastic SyndromePreclinical
Germany
09 Jun 2014
High Risk Myelodysplastic SyndromePreclinical
United States
09 Jun 2014
High Risk Myelodysplastic SyndromePreclinical
Italy
09 Jun 2014
High Risk Myelodysplastic SyndromePreclinical
France
09 Jun 2014
High Risk Myelodysplastic SyndromePreclinical
Spain
09 Jun 2014
High Risk Myelodysplastic SyndromePreclinical
United Kingdom
09 Jun 2014
High Risk Myelodysplastic SyndromePreclinical
Israel
09 Jun 2014
Myelodysplastic SyndromesPreclinical--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
11
Donor lymphocyte infusion+Flotetuzumab
gwqhbunkps(zcrfqojqye) = mcrmzagcsr nsovugqzke (wqirrufuix, apermmjhyf - grptztvfgs)
-
06 Dec 2024
Phase 1/2
88
(bmxjbiqgvx) = qogykmttbh errnoksjpl (ohrargrktk )
Positive
11 Feb 2021
Not Applicable
-
ztimrjzsji(rpzfyywbbv) = unwfqyufhr lxdmrinecq (vwyapxgvva )
-
14 Jun 2019
ztimrjzsji(rpzfyywbbv) = okystkhonu lxdmrinecq (vwyapxgvva )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free